Literature DB >> 6830529

Auditory middle-latency responses in humans.

O Ozdamar, N Kraus.   

Abstract

Middle-latency responses (MLR) in humans were studied using an unconventional recording technique with wide bandpass filters. Such filtering permitted simultaneous recording of the auditory brain stem response (ABR) thus facilitating comparisons between the two responses. Effects of sedation (chloral hydrate and diazepam), stimulus-related properties and the coronal distribution of MLRs were examined. Mild sedatives did not appear to affect either MLRs or ABRs. MLRs differed from ABRs in their stimulus-related properties, implying that the neuronal mechanisms underlying their generation are not the same. The amplitude of the MLR component, Pa, was largest at the vertex and symmetrically distributed over the temporal lobes. MLR components Na and Pa and ABR wave V were reliably obtained in all subjects at moderate and high stimulus intensities. At low stimulus levels, however, the detectability of wave V was more robust than the middle-latency components. Thus ABR appears to be the test of choice when hearing sensitivity is in question. MLRs are likely to be most clinically useful in patients with neurological or central auditory processing disorders.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830529     DOI: 10.3109/00206098309072768

Source DB:  PubMed          Journal:  Audiology        ISSN: 0020-6091


  14 in total

1.  Auditory middle latency responses in children with specific language impairment.

Authors:  Saud S Al-Saif; Mohamed M Abdeltawwab; Mahmoud Khamis
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-03       Impact factor: 2.503

2.  Differences by sex, ear, and sexual orientation in the time intervals between successive peaks in auditory evoked potentials.

Authors:  Dennis McFadden; Michelle D Hsieh; Adrian Garcia-Sierra; Craig A Champlin
Journal:  Hear Res       Date:  2010-09-27       Impact factor: 3.208

3.  The decomposition of the middle latency auditory evoked potential (MLAEP) Pa component into superficial and deep source contributions.

Authors:  G P Jacobson; C W Newman
Journal:  Brain Topogr       Date:  1990       Impact factor: 3.020

4.  Auditory middle-latency responses in patients with localized and non-localized lesions of the central nervous system.

Authors:  Y Kaseda; S Tobimatsu; T Morioka; M Kato
Journal:  J Neurol       Date:  1991-12       Impact factor: 4.849

5.  Lateralization and Binaural Interaction of Middle-Latency and Late-Brainstem Components of the Auditory Evoked Response.

Authors:  Andrew R Dykstra; Daniel Burchard; Christian Starzynski; Helmut Riedel; Andre Rupp; Alexander Gutschalk
Journal:  J Assoc Res Otolaryngol       Date:  2016-05-19

6.  The normal scalp topography of the middle latency auditory evoked potential Pa component following monaural click stimulation.

Authors:  G P Jacobson; A S Grayson
Journal:  Brain Topogr       Date:  1988       Impact factor: 3.020

7.  Selecting the best tone-pip stimulus-envelope time for estimating an objective middle-latency response threshold for low- and middle-tone sensorineural hearing losses.

Authors:  Z M Xu; E De Vel; B Vinck; P Van Cauwenberge
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

8.  Effects of benzodiazepines on mid-latency auditory evoked potentials.

Authors:  D Schwender; S Klasing; C Madler; E Pöppel; K Peter
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

9.  Auditory middle latency response in children with learning difficulties.

Authors:  Ana Claudia Figueiredo Frizzo; Myriam Lima Issac; Angela Cristina Pontes-Fernandes; Pedro de Lemos Menezes; Carolina Araújo Rodrigues Funayama
Journal:  Int Arch Otorhinolaryngol       Date:  2012-07

10.  Change in auditory evoked potential index and bispectral index during induction of anesthesia with anesthetic drugs.

Authors:  Sachiko Matsushita; Shinya Oda; Kei Otaki; Masaki Nakane; Kaneyuki Kawamae
Journal:  J Clin Monit Comput       Date:  2014-11-27       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.